Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

With the effective control of infectious diseases in many parts of the world, chronic, non-communicable diseases have become the major cause of death and disability. Monoclonal antibodies (mAbs) have become an important class of drugs for the treatment of such diseases. Nevertheless, mAbs suffer from major shortcomings in a chronic setting: most notably, generation of anti-antibodies and high cost of goods. Here, we discuss a novel approach to treat chronic diseases based on active rather than passive immunization and contrast the 2 treatment modalities to highlight their respective advantages and disadvantages.

Original publication

DOI

10.1016/j.vaccine.2013.02.001

Type

Journal article

Journal

Vaccine

Publication Date

03/04/2013

Volume

31

Pages

1777 - 1784

Keywords

Antibodies, Monoclonal, Chronic Disease, Humans, Immunization, Passive, Immunotherapy, Active, Patient Compliance, Treatment Failure